Press Releases

October 12, 2020
Gossamer Bio Announces Presentation of GB004 Phase 1b Clinical Data at United European Gastroenterology Virtual Week 2020 and Additional Program Updates
- Newly disclosed data build on topline results and continue to support GB004’s differentiated approach of targeting epithelial barrier restoration in patients with ulcerative colitis - - GB004 demonstrated superior barrier protection compared to tofacitinib in pre-clinical human monolayer assay -
Additional Formats
September 10, 2020
Gossamer Bio Announces Participation in Upcoming Investor Conferences
SAN DIEGO --(BUSINESS WIRE)--Sep. 10, 2020-- Gossamer Bio, Inc.   (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its
Additional Formats
Displaying 1 - 10 of 22